Amnion-derived cells as a reliable resource for next-generation regenerative medicine.
Level 5 - mechanism / opinion, no new human data
Narrative review of bench and animal research without human trial data
PubMed 31272680 · doi:10.1016/j.placenta.2019.06.381
What was done
This narrative review synthesized the properties of placenta- and amnion-derived cell types (epithelial, mesenchymal, and endothelial), their transdifferentiation capabilities, methods for generating amnion-derived induced pluripotent stem cells (AM-iPSCs), and their applications in preclinical disease models based on the literature.
What was found
The abstract reports no numerical data. It notes that amnion-derived cells undergo chondrogenesis and cardiomyogenesis upon transcription factor introduction, that AM-iPSCs display multipotency and stable immortality with distinct gene expression profiles, and that preclinical proof of concept was established in a mouse model of muscular dystrophy.
Why it matters
Amniotic membrane provides a readily accessible, non-invasive source of diverse allogeneic cells that may overcome logistical hurdles in cell-based regenerative medicine.
Limits
The abstract contains no quantitative effect sizes, systematic search methodology, or human clinical trial data. Evidence is restricted to in vitro and mouse models, without addressing potential immunogenicity, oncogenicity, or long-term engraftment challenges in humans.
Cited by
- supports The human placenta is a rich source of pluripotent stem cells that can differentiate into heart, liver, or brain cells.